| Autor: |
Nonthakorn Hantrakun, Wanwarang Wongcharoen, Kitti Thiankhaw, Lalita Norasetthada, Adisak Tantiworawit, Ekarat Rattarittamrong, Thanawat Rattanathammethee, Sasinee Hantrakool, Pokpong Piriyakhuntorn, Teerachat Punnachet, Piangrawee Niprapan, Chatree Chai-Adisaksopha |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of thrombosis and thrombolysis. |
| ISSN: |
1573-742X |
| Popis: |
Dabigatran is commonly used in atrial fibrillation (AF) or venous thromboembolism (VTE). However, there was limited data on dabigatran levels in Asian patients. This study aimed to investigate plasma levels of dabigatran 110 mg (D110) or 150 mg (D150) twice daily and their impact on clinical outcomes in Thai patients. This was a prospective cohort study including patients who were diagnosed with AF or VTE and were prescribed either D110 or D150. Plasma dabigatran levels were measured using the diluted thrombin time method. All patients were observed for bleeding and thrombotic complications for 12 months after enrollment. Ninety patients were included in the study (45 in the D110 group and 45 in the D150 group). For the D110 group, there was no significant difference in trough and peak levels in patients with creatinine clearance (CrCl) 50 ml/min compared to those with CrCl ≥ 50 ml/min. For the D150 group, patients with CrCl 50 ml/min had significantly higher trough and peak levels compared to those with CrCl ≥ 50 ml/min (P = 0.016 for trough, P = 0.005 for peak). Multivariate regression analysis showed females and low CrCl were independent risk factors for high dabigatran levels. Most patients (83.33%) who experienced bleeding complications had peak levels within the expected range. D150 was associated with higher plasma dabigatran levels, especially in those with impaired renal function. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink